Please assess the completion status of the following clinical trial:

Trial Title: Maintenance of Platelet Inhibition With Cangrelor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* 18 Years of Age~* Non emergent coronary bypass graft surgery~* Received a thienopyridine within 48 hours prior to enrollment~Exclusion Criteria:~* Confirmed or suspected pregnancy~* Cerebrovascular accident within one yar~* Intracranial neoplasm~* History of bleeding diathesis~* Thrombocytopenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Cangrelor (Type: EXPERIMENTAL): Cangrelor was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): A placebo infusion was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days, to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).